MYO1G

Across TCGA pan-cancer cohorts, MYO1G Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYO1G data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MYO1G Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO1G expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

ACC, UCEC, and LUSC are the cancer types where MYO1G Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.068	0.674	<.001	26	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	II,III,IV	0.428	0.746	.040	3	view →
COAD	OS	Median	All	0.907	0.594	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYO1G–ACC (DFS)

Open the ACC breakdown →